Clinical Operations
Clinical Project ManagementStudy Monitoring and Site ManagementTrial Master File and Document ManagementQuality and Vendor Management SystemsStudy DocumentsRegulatory Affairs
Regulatory StrategyRegulatory WritingAgency Communications and SubmissionsDocument Editorial, QC and SubmissionQC, Review and RedactionLegal RepresentationPharmacovigilanceILAP SubmissionsMedical Communications
Publication PlanningStrategic CommunicationsScientific CommunicationsMedical EducationMedical IllustrationGrant Applications and Project PartnershipNiche partnered closely with DemeRx, a clinical-stage biopharmaceutical company, to support the successful launch of a complex clinical study. From the outset, Niche engaged with DemeRx to understand the unique requirements of their program and rapidly identified a capable clinical site equipped to deliver the study efficiently and in alignment with the protocol’s demands. Beyond site identification and arranging for IMP management, Niche took full ownership of regulatory preparation—developing and coordinating the submission of all required documentation, including ethics and regulatory authority applications. The collaborative, detail-oriented approach ensured the study passed through approval processes smoothly and without unnecessary delays.
Cleothena, a newly established biotech company with a promising innovative medicine in development, has found its progress stalled—not due to scientific limitations, but because of the pressing need for robust, high-quality regulatory documentation.
DemeRx is aUS-based clinical stage pharmaceutical development company advancing drug candidates as therapies for addiction. It is currently evaluating patient data which demonstrate that a single dose of ibogaine may be sufficient to detoxify patients with opioid dependence and diminish drug cravings for extended time periods. As part of their clinical plan, DemeRx is evaluating the safety and pharmacokinetics of ibogaine in normal healthy volunteers and in patients with opioid abuse problems. It is hoped that these trials will demonstrate the use of ibogaine as an effective, non-opioid addiction treatment for withdrawal management and relapse prevention with better outcomes for patients suffering from alcohol and opioid use disorders.
DemeRx, a newly established biotech company with a promising innovative medicine in development found its progress delayed—not due to scientific limitations, but because of the pressing need for identifying a Phase I site the conduct their study and robust, high-quality regulatory documentation for the trial submission. The solution to DemRx’s dilemmas to engage Niche as a service provider known for its agility, strong relationship with most of the UK's Phase I sites and a deep regulatory expertise. Through rapid contracting and seamless onboarding, Niche was able to quickly mobilise a skilled team that immediately grasped the nuances of DemeRx's requirements.
In addition to operational and regulatory support, Niche provided strategic oversight to ensure trial quality and compliance throughout the study lifecycle. This included establishing a clinical monitoring plan, coordinating on-site activities and providing ongoing quality assurance. Responding to a gap in DemeRx’s leadership structure, Niche also assisted in the successful identification and onboarding of an interim Chief Medical Officer, ensuring continuity of medical oversight and regulatory representation. The end-to-end support offered by Niche not only de-risked the study’s start-up phase but also strengthened DemeRx’s clinical infrastructure during a critical stage of development.